RX South DBA RX3 Compounding Pharmacy LLC

CLOSEOUT LETTER RX South DBA RX3 Compounding Pharmacy LLC MARCS-CMS 440735 — June 26, 2019 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Christopher K. Currin, R.Ph. Recipient Title Co-Owner RX South DBA RX3 Compounding Pharmacy LLC 12230 Iron Bridge Rd. Suite C Chester , VA 23831-1534 United States Issuing Office: Center for Drug Evaluation and Research 10 Waterview Blvd. 3rd FL Parsippany , NJ 07054 United States (973) 331-4900 Dear Mr. Currin: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter dated October 23, 2014. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Craig Swanson Acting Program Division Director/District Director Office of Manufacturing Quality Operations Division I/New Jersey District Content current as of: 07/02/2019 Regulated Product(s) Drugs